Sutro Biopharma (STRO) Non-Current Assets (2017 - 2025)

Sutro Biopharma's Non-Current Assets history runs 9 years deep, the most recent figure standing at $22.9 million for Q4 2025.

• In Q4 2025, Non-Current Assets fell 47.82% year-over-year to $22.9 million; the TTM figure through Dec 2025 stood at $115.2 million (down 37.51% YoY), while the FY2025 annual figure was $22.9 million, down 47.82% from the prior year.
• Non-Current Assets came in at $22.9 million for Q4 2025 at Sutro Biopharma, down from $27.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $122.9 million in Q4 2021 to a low of $22.9 million in Q4 2025.
• A 5-year average of $58.1 million and a median of $51.7 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 708.24% in 2021 and tumbled 56.23% in 2022, its largest moves.
• Sutro Biopharma's Non-Current Assets stood at $122.9 million in 2021, then tumbled by 56.23% to $53.8 million in 2022, then retreated by 8.55% to $49.2 million in 2023, then dropped by 10.77% to $43.9 million in 2024, then slumped by 47.82% to $22.9 million in 2025.
• According to Business Quant data, Non-Current Assets over the past three periods registered $22.9 million, $27.5 million, and $30.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison